

Haqq, L., McFarlane, J., Dieberg, G., & Smart, N. (2015). The Effect of Lifestyle Intervention on Body Composition, Glycemic Control, and Cardiorespiratory Fitness in Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis. *International Journal of Sport Nutrition and Exercise Metabolism*, *25*(6), 533–540. http://dx.doi.org/10.1123/ijsnem.2013-0232

Downloaded from <u>e-publications@UNE</u> the institutional research repository of the University of New England at Armidale, NSW Australia.

Note: This article will be published in a forthcoming issue of the *International Journal of Sport Nutrition and Exercise Metabolism*. This article appears here in its accepted, peerreviewed form; it has not been copyedited, proofed, or formatted by the publisher.

Section: Original Research

Article Title: The Effect of Lifestyle Intervention on Body Composition, Glycaemic Control and Cardio-Respiratory Fitness in Women With Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis

Authors: Liza Haqq, James McFarlane, Gudrun Dieberg and Neil Smart

Affiliations: University of New England, School of Science and Technology, Armidale, NSW, Australia.

Journal: International Journal of Sport Nutrition and Exercise

Acceptance Date: January 23, 2014

©2014 Human Kinetics, Inc.

DOI: http://dx.doi.org/10.1123/ijsnem.2013-0232

The Effect of Lifestyle Intervention on Body Composition, Glycaemic Control and Cardio-respiratory Fitness in Women with Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis

Liza Haqq, James McFarlane, Gudrun Dieberg and Neil Smart University of New England, School of Science and Technology, Armidale, NSW, Australia 2351

Address for Correspondence: Associate Professor Neil Smart

School of Science and Technology

University of New England

Armidale NSW 2351 Australia

Tel: +61 2 6773 4076 Fax: +61 2 6773 5011

E-mail:nsmart2@une.edu.au

Number of Words: Abstract : 249

Main Text : 2621 (Excluding references)

by Hagg L, McFarlane J, Dieberg G, Smart N

International Journal of Sport Nutrition and Exercise Metabolism

© 2014 Human Kinetics, Inc.

ABSTRACT

Introduction: Polycystic Ovarian Syndrome (PCOS) affects 18-22% women of reproductive age. We conducted a systematic review and meta-analysis to quantify expected benefits of lifestyle (exercise and dietary) interventions on various clinical outcomes in PCOS. **Methods**: Potential studies were identified by conducting systematic search of Pub Med, CINAHL and Cochrane controlled trials registry (1966 to April 2013) using key concepts of PCOS, exercise, dietary and lifestyle interventions. Results: Significant improvements were seen in women who received lifestyle intervention versus usual care, in body composition parameters of body mass index (BMI), mean difference (MD) -1.12 kg.m⁻² (95%CI -0.22 to -0.03, P=0.009), body weight MD -3.42 kg (95%CI -4.86 to -1.99, P<0.00001), waist circumference MD -1.64 cm (95%CI -2.09 to -1.19, P<0.00001), waist hip ratio MD -0.03 (95%CI -0.05 to -0.01, P=0.0002) and body fat % MD -1.71% (95%CI -3.10 to -0.32, P=0.02). Insulin improved significantly, MD -1.10 pmol/L (95%CI -2.05 to -0.16, P=0.02). Lipid profile improved, total cholesterol MD -0.09 mmol/L (95%CI -0.14 to -0.04, P=0.0007) and low density lipoprotein (LDL) MD -0.15 mmol/L (95%CI -0.23 to -0.07, P=0.0003). C-reactive protein (CRP) was significantly lower, MD -0.47 mmol/L (95%CI -0.80 to -0.15, P=0.004). Significant improvements were also observed in cardio-respiratory fitness with resting heart rate MD -1.89 beats.min⁻¹ (95%CI -2.90 to -0.88, p=0.0002) and peak VO₂ MD 5.09 ml.kg⁻¹ .min⁻¹ (95% CI 3.13 to 7.05, P<0.00001). **Conclusions**: Our analyses suggest lifestyle intervention is optimal for improving body composition parameters, insulin, total and LDLcholesterol, CRP and cardio-respiratory fitness in women with PCOS.

With Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis"

by Haqq L, McFarlane J, Dieberg G, Smart N

International Journal of Sport Nutrition and Exercise Metabolism

© 2014 Human Kinetics, Inc.

INTRODUCTION

Polycystic Ovarian Syndrome (PCOS) was first reported in the 1930s by Stein and Leventhal [1]. This is the most common endocrine disorder affecting up to 18-22% of reproductive age women [2]. PCOS is characterised by clinical or biochemical hyperandrogenism [excess androgens which lead to acne, scalp hair loss, excessive facial and body hair (hirsutism)], insulin resistance, oligo/amenorrhea (infrequent or no menstruation), polycystic ovaries and infertility or reduced fertility [3, 4]. Physical inactivity and obesity work together with the genetic post receptor defects and lead to insulin resistance and hyperinsulinaemia [5, 6]. Insulin resistance and increased insulin levels aggravate the symptoms of PCOS in relation to biochemical and clinical hyperandrogenism. It is not the entire body weight but the distribution of that weight as fat in android (abdominal, central or visceral) pattern that increases health risks and worsens PCOS symptoms. Visceral adipose tissues produce adipocyte related hormones – Adiponectin and Leptin, which are insulin antagonists and contribute towards insulin resistance [7]. Insulin resistance and obesity increase the risk of glucose intolerance, dyslipidemia and diabetes mellitus (DM) considerably, which in turn increases cardiovascular risks [8].

Elevated levels of androgens (testosterone, dehydroepiandrosterone and and occasionally hyperprolactinaemia androstenedione) uncommon, are not hypothyroidism are present [9]. Most women with PCOS have elevated luteinizing hormone (LH) levels with normal oestrogen and follicle-stimulating hormone (FSH) production [10]. Increased insulin levels, obesity and hyperandrogenism contribute to the vicious cycle of anovulation which makes it hard for these women to conceive, often leading to depression and anxiety [11].

With Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis"

by Hagq L, McFarlane J, Dieberg G, Smart N

International Journal of Sport Nutrition and Exercise Metabolism

© 2014 Human Kinetics, Inc.

Hyperinsulinaemia leads to excess androgen production, so lowering insulin levels by

exercise training and weight loss (even as little as 5% of body mass) may reduce free

testosterone levels and restore ovulatory cycles, resulting in improved menstrual regularity,

ovulation, and pregnancy rates in many women with the disorder [12].

A systematic review was completed in 2009 by Harrison et al. [13] but these authors

did not conduct data pooling. In 2011 a systematic review and subsequent meta-analyses was

conducted by Moran et al.[14], but this analysis only included 6 published studies. Six more

recent lifestyle studies for PCOS mean that the volume of pooled data has doubled and the

number of outcome measures has been extended. We therefore conducted a systematic

review and meta-analysis; the primary aim was to quantify the expected benefits of exercise

training and dietary interventions on a range of clinical outcomes in women with PCOS.

METHODS

Search strategy

Potential studies were identified by conducting a systematic search using Pub Med,

www.ncbi.nlm.nih.gov/pubmed (1966 to April 2013). A search strategy can be seen in the

supplementary files. CINAHL and the Cochrane controlled trials registry were also searched

(1966 to April 2013). The search strategy included the key concepts of PCOS, dietary

therapy, lifestyle therapy and exercise training. These were combined with a sensitive search

strategy to identify randomized controlled trials. Reference lists of papers found were

scrutinized for new references. All identified papers were assessed independently by two

reviewers (NS and LH). Searches of published papers were also conducted up until April

2013.

With Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis"

by Haqq L, McFarlane J, Dieberg G, Smart N

International Journal of Sport Nutrition and Exercise Metabolism

© 2014 Human Kinetics, Inc.

Inclusions

Randomized, controlled trials of exercise alone or lifestyle (exercise and diet)

intervention in people with PCOS were included. There were no language restrictions.

Exclusions

Animal studies, review papers and non-randomized controlled trials were excluded.

Studies that did not have desired outcome measures or participants who were non-polycystic

ovary syndrome patients in either exercise, lifestyle (exercise and diet) or usual care groups

were excluded. Several authors were contacted and provided missing data, these data were

used in the analyses. Incomplete data or data from an already included study was excluded.

Studies using interventions other than lifestyle (e.g. electro acupuncture, ultrasound) were

excluded.

Studies included in the review

Our initial search identified 201 manuscripts, examination of the latest editions of

relevant journals yielded a further 32 manuscripts. Out of 233 studies, 28 were excluded at

first inspection as duplicates, 182 were removed after reading titles or abstracts, 13 of these

studies were not trials of lifestyle therapy in PCOS women, leaving 23 studies; 11 studies

were excluded for various reasons (see Supplementary Table 3), 12 studies were included for

analysis (see consort statement, Figure 1).

Data synthesis and Outcome Measures

Our lifestyle intervention groups were defined as exercise alone or exercise plus diet.

Our definition of usual care (comparator) groups could include sedentary control, placebo,

diet only or metformin. Analyses were only conducted on intervention versus comparator 1,

see Table 1. Data on all outcomes measures were archived in a database. Outcome measures

following interventions included body mass index (BMI), body weight, waist circumference

With Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis"

by Haqq L, McFarlane J, Dieberg G, Smart N

International Journal of Sport Nutrition and Exercise Metabolism

© 2014 Human Kinetics, Inc.

(WC), percentage body fat, waist hip ratio, glycaemic parameters (insulin, glucose and

homeostatic model assessment (HOMA) which quantifies insulin resistance), lipids, C-

reactive protein (CRP) and cardio-respiratory fitness (peak oxygen consumption (peak VO₂)

and heart rate).

Statistical analysis

Meta-analyses were completed for continuous data by using the change in the mean

and standard deviation of outcome measures as we did not wish to assume randomization

would adjust for baseline imbalance. Change in post-intervention mean was calculated by

subtracting baseline from post-intervention values. Change in the standard deviation of post-

intervention outcomes was calculated by using Revman 5.0 (Nordic Cochrane Centre

Denmark). Data required was either (i) 95% confidence interval data for pre-post intervention

change for each group or when this was unavailable (ii) actual P values for pre-post

intervention change for each group or if only the level of statistical significance was available

(iii) we used default P values (e.g. P<0.05 becomes P=0.049, P<0.01 becomes P=0.0099 and

P = not significant becomes P=0.05). A random effects inverse variance was used with the

effects measure of mean difference. Heterogeneity was quantified using Cochrane Q test [15].

Sensitivity analyses were conducted by removing studies of exercise and diet, leaving

exercise only studies, for the outcomes BMI, WC and peak VO₂. The purpose of sensitivity

analyses was to compare effect sizes of exercise alone with exercise and diet. Egger plots

[16] were provided to assess the risk of publication bias (see supplementary files). Study

quality was assessed by using a modified PEDro [17] score (out of 9 maximum score) as

blinding participants difficult in lifestyle studies. We used a 5% level of significance and

95% confidence intervals, figures were produced using Revman 5.

RESULTS

Our analyses included data from 12 studies [3, 4, 18-27], which yielded data on 668 women with PCOS. In seven studies the mean BMI indicated the participants were obese, three studies indicated women were overweight and in two studies it was unclear. Mean age of participants in all but one study was 21-32 years of age. Details of number of participants, duration of studies and withdrawals for included studies can be seen in Table 1. Supplementary Table 1 contains detailed descriptions of all interventions and comparator groups. Details of baseline characteristics of participants in included studies can be seen in supplementary files, Table 2. Details of the excluded randomized, controlled, trials [28-38] can be seen in supplementary file, Table 3.

Body Composition Parameters


Analysis of change in BMI showed significant improvement in lifestyle versus usual care groups, mean difference (MD) -1.12 kg.m⁻² (95%CI -0.22 to -0.03, P=0.009), see Figure 1.

Figure 1. Change in body mass index (BMI) in lifestyle versus usual care groups

	Lifestyle							Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI		
Bruner 2006	-0.3	0.3244	7	-1.2	0.9664	5	1.1%	0.90 [0.02, 1.78]			
Curi 2012	-1.7	1.6251	12	-1.2	2.065	15	0.4%	-0.50 [-1.89, 0.89]			
Hoeger 2004	-0.1	0.0095	6	-0.6	0.6488	7	3.8%	0.50 [0.02, 0.98]			
Hoeger 2008	-1.1	1.3158	8	0.6	0.8387	10	0.8%	-1.70 [-2.75, -0.65]			
Jedel 2011	0.01	0.0226	22	0.11	0.182	13	88.1%	-0.10 [-0.20, -0.00]			
Nybacka 2011	-1.9	1.9449	12	-1.74	1.5425	14	0.5%	-0.16 [-1.53, 1.21]			
Stener-Victorin 2009	-0.4	0.1937	5	0.5	0.4761	6	5.0%	-0.90 [-1.32, -0.48]			
Vigorito 2007	-1.3	3.2344	45	-0.1	4.4177	45	0.3%	-1.20 [-2.80, 0.40]			
Total (95% CI)			117			115	100.0%	-0.12 [-0.22, -0.03]	•		
Heterogeneity: Chi ² = 3	35.87, d	f = 7 (P	< 0.000	001); I ²	= 80%				_ 		
Test for overall effect: 2									Favours Lifestyle Favours Usual care		

When studies using exercise plus diet were removed to distinguish between exercise alone and exercise plus diet groups, MD was -0.15 kg.m⁻² (95% CI -0.24 to -0.05, P=0.003), see Figure 2. Note the 95% CI's in figures 1 and 2 overlap considerably.

Figure 2. Change in body mass index (BMI) in exercise alone versus usual care groups



Analysis of change in body weight showed significant improvement in lifestyle versus usual care groups, MD -3.42 (95%CI -4.86 to -1.99, P<0.00001), see Figure 3.

Figure 3. Change in body weight in lifestyle versus usual care groups

	l	ifestyle		U	sual care			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Bruner 2006	-0.8	0.865	7	-3.1	2.4966	5	39.6%	2.30 [0.02, 4.58]	-
Guzick 1994	-16.2	3.5427	6	0.001	0.001	6	25.6%	-16.20 [-19.04, -13.37]	
Nybacka 2011	-5.2	4.0022	12	-5.64	4.9334	14	17.4%	0.44 [-3.00, 3.88]	+
Thomson 2008	-10.1	5.0273	18	-8.6	4.8495	14	17.4%	-1.50 [-4.94, 1.94]	
Total (95% CI)			43			39	100.0%	-3.42 [-4.86, -1.99]	•
Heterogeneity: Chi ² =					$I^2 = 97\%$				-20 -10 0 10 20
Test for overall effect	Z = 4.6	8 (P < 0.	00001)						Favours Lifestyle Favours Usual Care


Waist circumference (WC) was significantly reduced for lifestyle versus usual care groups, MD -1.64 cm (95%CI -2.09 to -1.19, P<0.00001), see Figure 4.

Figure 4. Change in WC in lifestyle versus usual care groups

8	ا	ifestyle		Ü	sual Care	2		Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	SD Total Weight IV, Fixed, 95% (IV, Fixed, 95% CI	IV, Fixed, 95% CI		
Bruner 2006	-5.2	5.5886	7	-5	3.9984	5	0.7%	-0.20 [-5.62, 5.22]			
Curi 2012	-6.7	5.2238	12	-1.5	3.6827	15	1.7%	-5.20 [-8.69, -1.71]			
Hoeger 2008	-1	1.1961	8	0.6	0.8387	10	21.2%	-1.60 [-2.58, -0.62]			
Stener-Victorin 2009	-0.63	0.3051	5	0.94	0.5696	6	72.6%	-1.57 [-2.10, -1.04]			
Thomson 2008	-11.7	5.6305	18	-10.8	5.5423	14	1.3%	-0.90 [-4.80, 3.00]			
Vigorito 2007	-2.7	5.0854	45	-0.2	8.1501	45	2.6%	-2.50 [-5.31, 0.31]			
Total (95% CI)			95			95	100.0%	-1.64 [-2.09, -1.19]	•		
Heterogeneity: Chi ² =				$I^2 = 0\%$					-4-5 0 3 4		
Test for overall effect: $Z = 7.15$ (P < 0.00001)									Favours Lifestyle Favours Usual Care		

When studies using exercise plus diet were removed to distinguish between exercise alone and exercise plus diet groups, MD was -0.51(95% CI -0.67 to -0.34, P<0.00001), see Figure 5.

Figure 5. Change in WC in exercise versus usual care groups



Waist-Hip ratio was significantly lower for lifestyle versus usual care groups, MD - 0.03 (95%CI -0.05 to -0.01, P=0.0002), see Figure 6.

Figure 6. Change in waist-hip ratio in lifestyle versus usual care groups

	l	ifestyle.		Us	ual Care			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Guzick 1994	-0.03	0.0284	6	0.0001	0.0001	6	49.9%	-0.03 [-0.05, -0.01]	-
Vigorito 2007	-0.04	0.0753	45	-0.01	0.0188	45	50.1%	-0.03 [-0.05, -0.01]	•
Total (95% CI)			51			51	100.0%	-0.03 [-0.05, -0.01]	♦
Heterogeneity: Chi ² = Test for overall effect				$I^2 = 0\%$					-0.2 -0.1 0 0.1 0.2 Favours Lifestyle Favours Usual Care

Body Fat % was significantly lower for lifestyle versus usual care groups, MD -1.71% (95%CI -3.10 to -0.32, P=0.02), see Figure 7.

Figure 7. Change in body fat % in lifestyle versus usual care groups

	l	ifestyle.		U	sual Care	2		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Nybacka 2011	-0.84	2.7858	12	-1.66	2.8231	14	41.5%	0.82 [-1.34, 2.98]	-
Thomson 2008	-4.4	2.6142	18	-0.9	2.5979	14	58.5%	-3.50 [-5.32, -1.68]	-
Total (95% CI)			30			28	100.0%	-1.71 [-3.10, -0.32]	•
Heterogeneity: Chi ² =); $I^2 = 8$	39%				-10 -5 0 5 10
Test for overall effect:	Z = 2.4	1 (P = 0.	02)						Favours Lifestyle Favours Usual Care

Glycaemic Parameters

Insulin levels were significantly lower for lifestyle versus usual care groups, MD - 1.10 pmol/L (95%CI -2.05 to -0.16, P=0.02), see Figure 8.

Figure 8. Change in insulin in lifestyle versus usual care groups

	Lifestyle				sual Care			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Bruner 2006	-4.92	4.658	6	-18.55	11.5618	4	0.6%	13.63 [1.70, 25.56]	
Guzick 1994	-2.3	2.1775	6	-0.69	0.6575	6	27.1%	-1.61 [-3.43, 0.21]	
Hoeger 2008	-4.3	5.1434	8	2.7	3.7743	10	4.9%	-7.00 [-11.26, -2.74]	
Nybacka 2011	-3.45	9.2385	12	-2.85	7.7592	14	2.0%	-0.60 [-7.22, 6.02]	
Stener-Victorin 2009	-1.6	1.2886	5	-1.4	1.3341	6	37.2%	-0.20 [-1.75, 1.35]	+
Thomson 2008	-3.7	5.6305	18	-4.2	5.3691	14	6.1%	0.50 [-3.33, 4.33]	
Vigorito 2007	-1.8	4.4785	45	-0.2	5.2637	45	22.0%	-1.60 [-3.62, 0.42]	*
Total (95% CI)			100			99	100.0%	-1.10 [-2.05, -0.16]	•
Heterogeneity: $Chi^2 = 1$	15.73, d	f = 6 (P =	= 0.02)	$I^2 = 629$	6				-20 -10 0 10 20
Test for overall effect:	Z = 2.28	P = 0.0	(2)						Favours Lifestyle Favours Usual Care

Glucose levels were not significantly lower for lifestyle versus usual care groups, MD -0.02 mmol/L (95%CI -0.04 to 0.00, P=0.06), see supplementary file, Figure S1.

HOMA was not significantly different for lifestyle versus usual care groups, MD 0.10 (95%CI -0.22 to 0.42, P=0.56), see supplementary file, Figure S2.

Lipid Profile

There was no significant difference in triglycerides between lifestyle versus usual care groups, MD 0.19 mmol/L (95%CI -0.04 to 0.42, P=0.11), see supplementary Figure S3.


Total cholesterol was significantly lower in lifestyle versus usual care groups, MD - 0.09 mmol/L (95%CI -0.14 to -0.04, P=0.0007), see Figure 9.

Figure 9. Change in total cholesterol in lifestyle versus usual care groups

	Li	festyle		Us	ual Care			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Hoeger 2008	-0.0598	0.0715	8	-0.26	0.3635	10	5.0%	0.20 [-0.03, 0.43]	
Thomson 2008	-0.52	0.6837	18	-0.32	0.6581	14	1.2%	-0.20 [-0.67, 0.27]	
Vigorito 2007	-0.0517	0.1265	45	0.0517	0.1326	45	93.7%	-0.10 [-0.16, -0.05]	•
Total (95% CI)			71			69	100.0%	-0.09 [-0.14, -0.04]	•
Heterogeneity: Chi ² = Test for overall effect				= 69%					-0.5 -0.25 0 0.25 0.5
rest for overall effect	. 2 - 3.37	r – 0.00	07)						Favours Lifestyle Favours Usual Care

LDL cholesterol was significantly lower in lifestyle versus usual care groups, MD - 0.15 mmol/L (95%CI -0.23 to -0.07, P=0.0003), see Figure 10.

Figure 10. Change in LDL in lifestyle versus usual care groups



HDL was not significantly different in lifestyle versus usual care groups, MD -0.01 mmol/L (95%CI -0.04 to 0.02, P=0.51), see supplementary Figure S4.

C-Reactive protein (CRP)

Inflammatory marker CRP was significantly lower in lifestyle versus usual care groups, MD --0.47 mmol/L (95%CI -0.80 to -0.15, P=0.004), see Figure 11.

Figure 11. Change in CRP in lifestyle versus usual care groups

	I	ifestyle		U	sual care			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Hoeger 2008	-0.7	0.8373	8	-0.08	0.1118	10	30.9%	-0.62 [-1.20, -0.04]	
Vigorito 2007	-0.31	0.5839	45	0.1	1.2032	45	69.1%	-0.41 [-0.80, -0.02]	-
Total (95% CI)			53			55	100.0%	-0.47 [-0.80, -0.15]	•
Heterogeneity: Chi ² =				$I^2 = 0$	6				-2 -1 0 1 2
Test for overall effect	Z = 2.8	7 (P = 0.	004)						Favours Lifestyle Favours Usual Care

Cardio-respiratory Fitness

Resting heart rate was significantly lower in exercise alone versus usual care groups, MD -1.89 beats.min⁻¹ (95%CI -2.90 to -0.88, P=0.0002), see Figure 12.

Figure 12. Change in resting heart rate in exercise alone versus usual care groups

	ı	ifestyle		U	sual Care	2		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Stener-Victorin 2009	-4.2	1.6684	5	0.3	0.1532	6	47.2%	-4.50 [-5.97, -3.03]	-
Stener-Victorin 2012	0.1	0.2678	30	-1.8	3.2504	15	37.5%	1.90 [0.25, 3.55]	-
Vigorito 2007	-2.2	6.5803	45	0.9	5.8782	45	15.3%	-3.10 [-5.68, -0.52]	
Total (95% CI)			80			66	100.0%	-1.89 [-2.90, -0.88]	•
Heterogeneity: Chi ² = 3 Test for overall effect:				001); I²	= 94%				-10 -5 0 5 10 Favours Lifestyle Favours Usual Care

Peak VO_2 improved significantly for lifestyle versus usual care groups, MD 5.09 ml.kg⁻¹ .min⁻¹ (95% CI 3.13 to 7.05, P<0.00001), see Figure 13.

Figure 13. Change in peak VO₂ lifestyle alone versus usual care groups

_	_	Lifestyle		U	sual Care	2		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Bruner 2006	9.4	10.1639	7	1.1	0.8859	5	6.7%	8.30 [0.73, 15.87]	
Jedel 2011	4.54	6.0373	22	0.27	0.4468	13	59.8%	4.27 [1.74, 6.80]	-
Vigorito 2007	6.1	11.4893	45	0.2	1.4812	45	33.5%	5.90 [2.52, 9.28]	-
Total (95% CI)			74			63	100.0%	5.09 [3.13, 7.05]	•
Heterogeneity: Chi ² = Test for overall effect									-10 -5 0 5 10 Favours Usual Care Favours Lifestyle

When studies using exercise plus diet were removed to distinguish between exercise alone and exercise plus diet groups MD was 4.86 (95% CI 2.83 to 6.88, P<0.00001), see Figure 14.

Figure 14. Change in peak VO₂ in exercise alone versus usual care groups

	Exe	Exercise Alone			sual Care	Э		Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixed	I, 95% CI	
Jedel 2011	4.54	6.0373	22	0.27	0.4468	13	64.1%	4.27 [1.74, 6.80]			-	_
Vigorito 2007	6.1	11.4893	45	0.2	1.4812	45	35.9%	5.90 [2.52, 9.28]				
Total (95% CI)			67			58	100.0%	4.86 [2.83, 6.88]			•	>
Heterogeneity: Chi ² = Test for overall effect:			, .	= 0%					-10 -5 Favours Usu	al Care	5 Favours I	10 Exercise Alon

STUDY QUALITY

In terms of study quality, median score was 7, with four studies scoring 6, four studies scoring 7, three studies scoring 8 and one study scoring 9, using a modified PEDro scale (out of 9). Details of the scores and PEDro scale are given in the supplementary file, Table 4. Egger plots showed little or no evidence of publication bias (see supplementary Files, Figures S5-S9).

DISCUSSION

This work presents a meta-analysis of the effectiveness of lifestyle (exercise and diet) intervention for polycystic ovarian syndrome (PCOS). These analyses were conducted using

With Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis"

by Hagq L, McFarlane J, Dieberg G, Smart N

International Journal of Sport Nutrition and Exercise Metabolism

© 2014 Human Kinetics, Inc.

a range of prognostic markers of PCOS as outcome measures. There was a significant

improvement in body composition parameters (BMI, body weight, waist circumference,

waist-hip ratio and body fat %), total- and LDL-cholesterol, C-reactive protein, insulin and

cardio-respiratory parameters (resting heart rate and peak VO₂). These data have clinical

implications for improving reproductive function in overweight/obese women with PCOS

using non-pharmacological methods.

Lifestyle with or without dietary intervention produced favourable changes in body

composition measures; WC, waist-hip ratio, percentage body fat and BMI, suggesting that a

large proportion of weight lost was adipose tissue. Previously, combined diet and exercise

interventions for PCOS participants reported reductions in body fat but also muscle mass

[23]. Previous work has suggested it is exercise, not dietary, intervention that provides the

greatest changes in body composition and glycaemic control in women with PCOS [23].

Previous work also suggests modest weight reduction of about 5-10% might play the most

significant role in restoration of ovulation and fertility in obese women with PCOS [21, 39].

The mean study duration of this analysis was 20 weeks; this duration may not be sufficient to

achieve 5-10% weight loss.

Exercise alone has been shown to improve fertility [23, 40] and this is most likely

mediated by improved insulin resistance [40]. Our analyses lend weight to the theory that

insulin sensitivity is improved with regular exercise training in women with PCOS, although

blood glucose was actually better in control groups. Our results suggest that optimal

reductions in measures related to central obesity (waist circumference and waist-hip-ratio)

require both exercise and dietary intervention. These reductions in central obesity are

accompanied by improvements in measures of glycaemic control. Previous work has

suggested that improved insulin sensitivity is closely related to improved waist circumference

With Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis"

by Hagq L, McFarlane J, Dieberg G, Smart N

International Journal of Sport Nutrition and Exercise Metabolism

© 2014 Human Kinetics, Inc.

and waist-hip ratio, which in turn is related to android (central) body fat morphology [41].

Previous work has hypothesized that either through exercise alone, or in combination with

appropriate dietary intervention, enhancements in insulin sensitivity is possible in women

with PCOS.

Our analyses demonstrated improved peak VO₂ and reduced resting heart rate after

completion of lifestyle therapy in women with PCOS. Vigorito et al. have previously shown

that in overweight women with PCOS insulin sensitivity and peak VO₂ are positively

correlated [27]. Moreover a 2006 review suggested: (i) Exercise may prevent reproductive

complications associated with maternal obesity. (ii) Obesity increases the risk of infertility

and miscarriage. (iii) Weight loss programs that incorporate diet and exercise are a cost-

effective fertility treatment that may also reduce the probability of obesity-related

complications during pregnancy. (iv) Regular exercise following conception may prevent

excessive gestational weight gain and reduce post-partum weight retention [42]. Our

measurements support the argument that higher levels of cardio-respiratory fitness are

associated with better fertility. The magnitude of change in peak VO₂ demonstrated here

would be noticeable to the participants and also clinically meaningful.

With respect to lipid profile, our analyses showed improvements in only Total- and

LDL-cholesterol. Previous work has suggested that exercise induced changes in lipid profiles

require a sustained lifestyle adherence program [43]. It may be that the included studies were

not of sufficient duration to induce lipid improvements [14, 44], although reduced CRP levels

indicate reduced systemic inflammation.

The sensitivity analyses for exercise only for the BMI, WC and peak VO₂ yielded

very similar effect sizes and statistical significance as combined diet and exercise

With Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis"

by Haqq L, McFarlane J, Dieberg G, Smart N

International Journal of Sport Nutrition and Exercise Metabolism

© 2014 Human Kinetics, Inc.

interventions. This suggests that exercise will improve these outcomes either in isolation or in

combination with dietary intervention.

In summary, previous work has suggested that exercise is superior to dietary

intervention for improving glycaemic control and body composition in women PCOS, our

data support this, although intuitively a combined exercise and dietary intervention approach

may yield superior results in trials lasting more than 20 weeks. We suspect there are currently

insufficient published data to separate the effects of exercise or dietary intervention.

The limitations of this study are that exercise prescriptions vary slightly, and several

studies used additional dietary interventions, although we conducted sub-analyses for BMI,

WC and peak VO₂ to account for this. Meta-analysis of continuous data is problematic; we

took the approach of adjusting for baseline difference in primary outcomes between

allocation groups by measuring pre-versus post-intervention change. In many cases we were

accurately able to calculate change in standard deviation, but in some cases where exact P-

values were not provided in included study reports we had to use default values e.g. P<0.05

or P<0.001 in our calculations which may have introduced errors. Moreover these errors may

have increased the measures of heterogeneity in our analyses which in some cases were high.

Finally, we acknowledge that other factors, especially those related to volume of exercise

(e.g. program duration) may explain some of the outcomes reported.

Conclusions

Our analyses suggest lifestyle intervention involving exercise are optimal for

improving body composition parameters, insulin, lipid profile (especially total and LDL-

cholesterol), CRP and cardio-respiratory fitness in women with PCOS.

Acknowledgments

None

© 2014 Human Kinetics, Inc.

REFERENCES

- 1. Stein, I.F. and M.L. Leventhal, *Amenorrhea associated with bilateral polycystic ovaries*. Am J Obstet Gynecol, 1935. **29**(2): p. 181-91.
- 2. March, W.A., V.M. Moore, K.J. Willson, et al., The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human reproduction, 2010. **25**(2): p. 544-551.
- 3. Jedel, E., F. Labrie, A. Oden, et al., Impact of electro-acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomized controlled trial. Am J Physiol Endocrinol Metab, 2011. **300**(1): p. E37-45.
- 4. Thomson, R.L., J.D. Buckley, M. Noakes, et al., The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome. J Clin Endocrinol Metab, 2008. **93**(9): p. 3373-80.
- 5. Cobin, R.H., W. Futterweit, J.E. Nestler, et al., American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. Endocr Pract, 2005. 11(2): p. 126-34.
- 6. Fauser, B.C., B.C. Tarlatzis, R.W. Rebar, et al., Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril, 2012. 97(1): p. 28-38 e25.
- 7. Hoeger, *Role of lifestyle modification in the management of polycystic ovary syndrome*. Best Practice & Research Clinical Endocrinology & Metabolism, 2006. **20**(2): p. 293-310.
- 8. Salley, K.E.S., E.P. Wickham, K.I. Cheang, et al., Position Statement: glucose intolerance in polycystic ovary syndrome—a position statement of the Androgen Excess Society. Journal of Clinical Endocrinology & Metabolism, 2007. **92**(12): p. 4546-4556.
- 9. Rachon, D., *Differential diagnosis of hyperandrogenism in women with polycystic ovary syndrome*. Exp Clin Endocrinol Diabetes, 2012. **120**(4): p. 205-9.
- 10. Beydoun, H.A., M.A. Beydoun, N. Wiggins, et al., Relationship of obesity-related disturbances with LH/FSH ratio among post-menopausal women in the United States. Maturitas, 2012. **71**(1): p. 55-61.
- 11. Jedel, E., M. Waern, D. Gustafson, et al., Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Human reproduction, 2010. **25**(2): p. 450-456.
- 12. Teede, H., A. Deeks and L. Moran, *Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan.* BMC Med, 2010. **8**: p. 41.
- 13. Harrison, C.L., C.B. Lombard, L.J. Moran, et al., Exercise therapy in polycystic ovary syndrome: a systematic review. Hum Reprod Update, 2011. 17(2): p. 171-83.
- 14. Moran, L.J., S.K. Hutchison, R.J. Norman, et al., Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev, 2011(7): p. CD007506.
- 15. Higgins JPT, G.S. (2011) Cochrane Handbook for Systematic Reviews of Interventions.

by Haqq L, McFarlane J, Dieberg G, Smart N

International Journal of Sport Nutrition and Exercise Metabolism © 2014 Human Kinetics, Inc.

- 16. Egger, M., G. Davey Smith, M. Schneider, et al., Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997. **315**(7109): p. 629-34.
- 17. Maher, C.G., C. Sherrington, R.D. Herbert, et al., Reliability of the PEDro scale for rating quality of randomized controlled trials. Phys Ther, 2003. **83**(8): p. 713-21.
- 18. Bruner, B., K. Chad and D. Chizen, *Effects of exercise and nutritional counseling in women with polycystic ovary syndrome*. Appl Physiol Nutr Metab, 2006. **31**(4): p. 384-91.
- 19. Curi, D.D., A.M. Fonseca, J.A. Marcondes, et al., Metformin versus lifestyle changes in treating women with polycystic ovary syndrome. Gynecol Endocrinol, 2012. **28**(3): p. 182-5.
- 20. Guzick, D.S., R. Wing, D. Smith, et al., Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril, 1994. **61**(4): p. 598-604.
- 21. Hoeger, K.M., L. Kochman, N. Wixom, et al., A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril, 2004. **82**(2): p. 421-9.
- 22. Hoeger, K.M., *Exercise therapy in polycystic ovary syndrome*. Semin Reprod Med, 2008. **26**(1): p. 93-100.
- 23. Nybacka, A., K. Carlstrom, A. Stahle, et al., Randomized comparison of the influence of dietary management and/or physical exercise on ovarian function and metabolic parameters in overweight women with polycystic ovary syndrome. Fertil Steril, 2011. **96**(6): p. 1508-13.
- 24. Stener-Victorin, E., E. Jedel, P.O. Janson, et al., Low-frequency electroacupuncture and physical exercise decrease high muscle sympathetic nerve activity in polycystic ovary syndrome. Am J Physiol Regul Integr Comp Physiol, 2009. **297**(2): p. R387-95.
- 25. Stener-Victorin, E., F. Baghaei, G. Holm, et al., Effects of acupuncture and exercise on insulin sensitivity, adipose tissue characteristics, and markers of coagulation and fibrinolysis in women with polycystic ovary syndrome: secondary analyses of a randomized controlled trial. Fertility and sterility, 2012. 97(2): p. 501-508.
- 26. Thomson, R.L., G.D. Brinkworth, M. Noakes, et al., The effect of diet and exercise on markers of endothelial function in overweight and obese women with polycystic ovary syndrome. Hum Reprod, 2012. **27**(7): p. 2169-76.
- 27. Vigorito, C., F. Giallauria, S. Palomba, et al., Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab, 2007. **92**(4): p. 1379-84.
- 28. Brown, A.J., T.L. Setji, L.L. Sanders, et al., Effects of exercise on lipoprotein particles in women with polycystic ovary syndrome. Med Sci Sports Exerc, 2009. **41**(3): p. 497-504.
- 29. Galletly, C., L. Moran, M. Noakes, et al., Psychological benefits of a high-protein, low-carbohydrate diet in obese women with polycystic ovary syndrome--a pilot study. Appetite, 2007. **49**(3): p. 590-3.
- 30. Karimzadeh, M.A. and M. Javedani, An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome. Fertil Steril, 2010. **94**(1): p. 216-20.

by Haqq L, McFarlane J, Dieberg G, Smart N

International Journal of Sport Nutrition and Exercise Metabolism © 2014 Human Kinetics, Inc.

- 31. Ladson, G., W.C. Dodson, S.D. Sweet, et al., Effects of metformin in adolescents with polycystic ovary syndrome undertaking lifestyle therapy: a pilot randomized double-blind study. Fertil Steril, 2011. **95**(8): p. 2595-8 e1-6.
- 32. Ladson, G., W.C. Dodson, S.D. Sweet, et al., The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. Fertil Steril, 2011. **95**(3): p. 1059-66 e1-7.
- 33. Ma, L.K., L.N. Jin, Q. Yu, et al., [Effect of lifestyle adjustment, metformin and rosiglitazone in polycystic ovary syndrome]. Zhonghua Fu Chan Ke Za Zhi, 2007. **42**(5): p. 294-7.
- 34. Moran, L.J., M. Noakes, P.M. Clifton, et al., Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab, 2003. **88**(2): p. 812-9.
- 35. Orio, F., F. Giallauria, S. Palomba, et al., Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women. Clin Endocrinol (Oxf), 2008. **68**(6): p. 976-81.
- 36. Otta, C.F., M. Wior, G.S. Iraci, et al., Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. Gynecol Endocrinol, 2010. **26**(3): p. 173-8.
- 37. Palomba, S., A. Falbo, F. Giallauria, et al., Six weeks of structured exercise training and hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: a randomized controlled trial. Hum Reprod, 2010. 25(11): p. 2783-91.
- 38. Thomson, R.L., J.D. Buckley, S.S. Lim, et al., Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. Fertil Steril, 2010. **94**(5): p. 1812-6.
- 39. Hoeger, K.M., *Role of lifestyle modification in the management of polycystic ovary syndrome.* Best Pract Res Clin Endocrinol Metab, 2006. **20**(2): p. 293-310.
- 40. Orio, F., S. Palomba, T. Cascella, et al., Lack of electrocardiographic changes in women with polycystic ovary syndrome. Clin Endocrinol (Oxf), 2007. **67**(1): p. 46-50.
- 41. Godoy-Matos, A.F., F. Vaisman, A.P. Pedrosa, et al., Central-to-peripheral fat ratio, but not peripheral body fat, is related to insulin resistance and androgen markers in polycystic ovary syndrome. Gynecol Endocrinol, 2009. **25**(12): p. 793-8.
- 42. Weissgerber, T.L., L.A. Wolfe, G.A. Davies, et al., Exercise in the prevention and treatment of maternal-fetal disease: a review of the literature. Appl Physiol Nutr Metab, 2006. **31**(6): p. 661-74.
- 43. Slentz, C.A., J.A. Houmard, J.L. Johnson, et al., Inactivity, exercise training and detraining, and plasma lipoproteins. STRRIDE: a randomized, controlled study of exercise intensity and amount. Journal of applied physiology (Bethesda, Md., 2007. 103(2): p. 432-42.
- 44. Durstine, J.L., P.W. Grandjean, P.G. Davis, et al., Blood lipid and lipoprotein adaptations to exercise: a quantitative analysis. Sports medicine (Auckland, N.Z, 2001. **31**(15): p. 1033-62.


Figure 1. Consort Statement.



Screening

Eligibility





by Haqq L, McFarlane J, Dieberg G, Smart N

International Journal of Sport Nutrition and Exercise Metabolism

© 2014 Human Kinetics, Inc.

Table 1: Included lifestyle intervention studies, duration, number of participants, intervention and comparator groups.

Study	Duration of study	Total participants (lifestyle group)	Withdrawal (number of people)	Intervention	Comparator 1	Comparator 2	Comparator 3
Bruner 2006 [18]	12 weeks	12(7)	None	Lifestyle	Diet		
Curi 2012 [19]	6 months	40(12)	13	Lifestyle	Metformin		
Guzick 1994 [20]	12 weeks	12(6)	None	Lifestyle	Usual Care		
Hoeger 2004 [21]	48 weeks	38(6)	15	Lifestyle and placebo	Placebo	Metformin	Lifestyle & Metformin
Hoeger 2008 [22]	24 weeks	43(8)	9	Lifestyle	Placebo	Metformin	Oral contraceptive
Jedel 2011 [3]	16 weeks	84(22)	25	Lifestyle (Exercise only)	Usual care	Low frequency electro- acupuncture	
Nybacka 2011 [23]	4 months	57(12)	14	Lifestyle	Diet	Exercise	
Stener-Victorin 2009 [24]	16 weeks	20(5)	None	Lifestyle (Exercise only)	Usual care	Low frequency electro- acupuncture	
Stener-Victorin 2012 [25]	16 weeks	84(30)	10	Lifestyle (Exercise only)	Usual care	Low frequency electro acupuncture	
Thomson 2008 [4]	20 weeks	94(18)	42	Lifestyle	Diet	Diet & combined aerobic- resistance exercise	
Thomson 2012 [26]	20 weeks	94 (16)	44	Lifestyle	Diet	Diet & combined aerobic- resistance exercise	

by Haqq L, McFarlane J, Dieberg G, Smart N
International Journal of Sport Nutrition and Exercise Metabolism

© 2014 Human Kinetics, Inc.

Study	Duration of study	Total participants (lifestyle group)	Withdrawal (number of people)	Intervention	Comparator 1	Comparator 2	Comparator 3
Vigorito 2007 [27]	3 months	90(45)	None	Lifestyle (Exercise only)	Usual care		